How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Genetically Engineered Animal Models and Services Market
- By Model Type: Knockout Models, Knockin Models, Transgenic Models, Conditional Models, Humanized Models
- By Animal Species: Mouse Models, Rat Models, Zebrafish Models, Rabbit Models, Non-Human Primate Models
- By Technology Platform: CRISPR/Cas9, TALENs, Zinc Finger Nucleases (ZFNs), RNA Interference (RNAi), Embryonic Stem Cell Modification
- By Service Type: Custom Model Generation, Model Breeding and Maintenance, Phenotyping Services, Genotyping Services, Cryopreservation and Repositories
- By End-User Application: Pharmaceutical and Biotechnology Research, Academic and Government Research, Toxicology and Safety Assessment, Agricultural Biotechnology, Regenerative Medicine Research
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Knockout Models leads By Model Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Genetically Engineered Animal Models and Services Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Model Type 5
Animal Species 5
Technology Platform 5
Service Type 5
End-User Application 5
Companies profiled
Charles River Laboratories International Inc.
Envigo RMS LLC (a part of Inotiv)
Taconic Biosciences Inc.
The Jackson Laboratory
GenOway SA
Cyagen Biosciences Inc.
Biocytogen Pharmaceuticals Co. Ltd.
Model Animal Research Center of Nanjing University (MARC)
GemPharmatech Co. Ltd.
Shanghai Model Organisms Center Inc.
Horizon Discovery Group plc
SAGE Labs (a division of BioIVT)
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Envigo RMS LLC (a part of Inotiv)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Taconic Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →The Jackson Laboratory
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →GenOway SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Cyagen Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Biocytogen Pharmaceuticals Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Model Animal Research Center of Nanjing University (MARC)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →GemPharmatech Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Shanghai Model Organisms Center Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Horizon Discovery Group plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →SAGE Labs (a division of BioIVT)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Transgenic Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Cyagen Biosciences
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,128M by 2033 · 7.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Knockout Models45.9
- Knockin Models11.1
- Transgenic Models16.1
- Conditional Models13.3
- Humanized Models13.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$937.0M → $1,695M · 7.7%
Europe$653.1M → $1,125M · 7.0%
Asia Pacific$596.3M → $959.6M · 6.1%
Latin America$369.1M → $668.3M · 7.7%
Middle East and Africa$283.9M → $483.6M · 6.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.632026
7.622027
7.652028
7.662029
7.682030
7.682031
7.682032
7.692033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories International Inc.15.6
- Envigo RMS LLC (a part of Inotiv)17.7
- Taconic Biosciences Inc.7.4
- The Jackson Laboratory7.3
- GenOway SA10.5
- Cyagen Biosciences Inc.13.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Model Type13.3%
Animal Species11.9%
Technology Platform33.8%
Service Type20.8%
End-User Application20.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.4
- Europe22.8
- Asia Pacific19.5
- Latin America13.6
- Middle East and Africa9.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | 97 | 80 | 82 | 83 | 82 | 93 | 86 |
| Envigo RMS LLC (a part of Inotiv) | 90 | 86 | 74 | 91 | 79 | 86 | 84 |
| Taconic Biosciences Inc. | 69 | 80 | 64 | 85 | 86 | 77 | 77 |
| The Jackson Laboratory | 73 | 66 | 79 | 75 | 60 | 69 | 70 |
| GenOway SA | 67 | 65 | 57 | 56 | 53 | 57 | 59 |
| Cyagen Biosciences Inc. | 60 | 69 | 57 | 53 | 64 | 48 | 59 |
| Biocytogen Pharmaceuticals Co. Ltd. | 51 | 42 | 55 | 49 | 51 | 60 | 51 |
| Model Animal Research Center of Nanjing University (MARC) | 45 | 50 | 37 | 50 | 53 | 37 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories International Inc.
- Envigo RMS LLC (a part of Inotiv)
- Taconic Biosciences Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Envigo RMS LLC (a part of Inotiv) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Taconic Biosciences Inc. | ◐ | ◐ | − | ◐ | ✓ | ✓ |
| The Jackson Laboratory | ◐ | ◐ | ✓ | ◐ | − | − |
| GenOway SA | ◐ | − | ◐ | − | ◐ | ◐ |
| Cyagen Biosciences Inc. | ◐ | ◐ | ◐ | − | ✓ | − |
| Biocytogen Pharmaceuticals Co. Ltd. | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Model Animal Research Center of Nanjing University (MARC) | ◐ | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Charles River Laboratories International Inc.86
2Envigo RMS LLC (a part of Inotiv)84
3Taconic Biosciences Inc.77
4The Jackson Laboratory70
5GenOway SA59
6Cyagen Biosciences Inc.59
7Biocytogen Pharmaceuticals Co. Ltd.51
8Model Animal Research Center of Nanjing University (MARC)45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Charles River Laboratories International Inc.Envigo RMS LLC (a part of Inotiv)
Challenger2
Strong scale, closing on the leaders.
Taconic Biosciences Inc.The Jackson Laboratory
Contender2
Focused players with pockets of strength.
GenOway SACyagen Biosciences Inc.
Niche2
Specialists in a single segment or region.
Biocytogen Pharmaceuticals Co. Ltd.Model Animal Research Center of Nanjing University (MARC)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Model Type in North America, then scale across Genetically Engineered Animal Models and Services Market — a $243M beachhead inside a $3.28B market.
Beachhead (SOM)$243Mobtainable near-term
Serviceable (SAM)$1.28Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Knockout Models
Best fit — highest urgency & budget in Model Type.
Economic buyer81 fit
Knockin Models
Strong fit — clear ROI and a fast path to value.
End user64 fit
Transgenic Models
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Model Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Animal Species & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology Platform
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel28%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Model Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Genetically Engineered Animal Models and Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified22%
Evaluation11%
Closed-won7%
$10.9KCAC
$65KLTV
5.9:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Genetically Engineered Animal Models and Services Market is a resilient opportunity — $1.24B by 2033, compounding at 5.3%.
TAM · 2025$825Mtoday
TAM · 2033$1.24Bforecast
CAGR5.3%2027–2033
Cumulative$9.20Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.24BTotal addressable market
SAM$455MServiceable available market
SOM$88MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.3% CAGR
Demand compounds through 2033, outpacing GDP across Model Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Model Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.24BLarge & growingTAM by 2033 at 5.3% CAGR
$455MServiceable nowreachable with today’s model
$88MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$970MBear3.4% CAGR
$1.24BBase5.3% CAGR
$1.59BBull6.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Animal Species optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Genetically Engineered Animal Models and Services Market — a $10.8B market by 2033. Plan: grow share from 5.5% to 11.3%.
Market size · 2033$10.8Btotal addressable
Market CAGR11.2%2027–2033
Target share11.3%from 5.5% today
Revenue ambition$1.22Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.5% | 11.3% | On track |
| Revenue | $614M | $1.22B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 31.8% | 41.8% | At risk |
| Customer retention | 86.4% | 96.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Model Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Animal Species capability
A defensible second engine — invest in Animal Species to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Model Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Animal Species
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $174M capacity & capability investment
- Greenlight bolt-on M&A in Animal Species
- Authorise North America expansion plan
- Fund R&D program for Model Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Genetically Engineered Animal Models and Services Market conversation — a $3.63B market you can size, segment and defend in minutes.
Market size · 2033$3.63Btotal opportunity
Growth9.4%CAGR to 2033
Addressable buyers1,433+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Model Type
Goal Grow share in Model Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 4 mopayback period
$73K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Charles River Laboratories International Inc.Envigo RMS LLC (a part of Inotiv)Taconic Biosciences Inc.The Jackson LaboratoryGenOway SACyagen Biosciences Inc.Biocytogen Pharmaceuticals Co. Ltd.Model Animal Research Center of Nanjing University (MARC)+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Genetically Engineered Animal Models and Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Genetically Engineered Animal Models and Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Genetically Modified (GMO) Seed Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportGenetically Modified Food Rapid Detection Test Strips Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportGenetically Modified Herbicide Resistance Test Strips Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportGenetically Modified Organism Corn Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportGenetics Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportGenital Herpes Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportGenital Warts Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportGenome Sequencing Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportGenomic Imprinting Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportGenomic Probe Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportGenomics Analytical Instruments Market
Market size, share, segmentation and regional forecast.
$558M market · 2025 base year
View reportGenomics And Proteomics Reagents, Research Kits and Analytical Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.